Goodnites Skin Tag and Wart Remover

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, "cauliflower-like" surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting tenderness and disrupting the normal footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be cleaned thoroughly prior to application. A thin layer of the product should be applied to the skin tag using the provided applicator. It is important to allow the application to dry completely. The application should be repeated twice daily for a duration of up to 4 weeks, or as directed by a healthcare professional.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated, infected, or reddened skin, as well as on genital warts or warts located on the face. Additionally, individuals with diabetes or poor blood circulation should avoid use due to the potential for adverse effects.

The product should not be applied near the eyes or mucous membranes to prevent irritation or injury.

Warnings and Precautions

External use of this product is strictly advised. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

This product should not be applied to irritated, infected, or reddened skin. It is contraindicated for use on genital warts or warts located on the face. Additionally, individuals with diabetes or those who exhibit poor blood circulation should refrain from using this product.

Users are advised to discontinue use if the condition being treated worsens or if excessive irritation develops. Should unexpected side effects occur, it is imperative to stop use and consult a healthcare professional. Caution is advised to avoid application near the eyes or mucous membranes.

While mild irritation may be a common occurrence, any excessive irritation warrants immediate cessation of use and consultation with a physician.

Side Effects

Patients should be aware that the product is intended for external use only. In clinical practice, there have been reports of adverse reactions that necessitate caution.

Common adverse reactions include worsening of the condition being treated, excessive irritation at the site of application, and the occurrence of unexpected side effects. In such instances, it is advised that patients discontinue use and consult a healthcare professional.

These reactions have been noted in both clinical trials and postmarketing experiences, underscoring the importance of monitoring for any changes in symptoms or the development of new adverse effects during treatment.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Goodnites Skin Tag and Wart Remover (salicylic acid 17%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication for external application only. It is contraindicated for use on irritated, infected, or reddened skin, as well as on genital warts or warts located on the face. Caution is advised for patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Application should be performed on a clean affected area, where a thin layer of the medication is applied to the skin tag using the provided applicator. The area must be allowed to dry fully after application. Treatment may be repeated twice daily for up to 4 weeks, or as directed by a healthcare professional.

Mild irritation may occur; however, if excessive irritation develops, or if the condition worsens or unexpected side effects arise, it is essential to consult a doctor. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is necessary. This medication should not be used near the eyes or mucous membranes.

Geriatric Use

There is no specific information regarding the use of Goodnites Skin Tag and Wart Remover in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this product to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment outcomes in this population.

Pregnancy

Safety during pregnancy has not been established for this medication. It is not recommended for use during pregnancy due to potential risks to the fetus. Healthcare professionals should consider the potential risks and benefits when prescribing this medication to pregnant patients or women of childbearing potential.

Lactation

There are no specific warnings or recommendations regarding the use of this product in lactating mothers. Additionally, there are no statements concerning the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Renal impairment may necessitate dosage adjustments for patients with reduced kidney function. It is important to monitor renal function tests in these patients to ensure safety and efficacy. Additionally, a reduced dose should be considered for patients with decreased creatinine clearance to mitigate the risk of adverse effects.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, it is important for healthcare professionals to remain vigilant and consider general principles of management in cases of suspected overdose with any medication.

Healthcare providers should monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention is warranted. Recommended actions include contacting a poison control center or seeking emergency medical assistance. Supportive care should be initiated as necessary, which may involve maintaining airway patency, providing supplemental oxygen, and administering intravenous fluids to manage hemodynamic stability.

Healthcare professionals are encouraged to refer to established clinical guidelines and protocols for the management of overdose situations, as these resources provide comprehensive strategies tailored to specific substances and their pharmacological profiles.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients that if the medication is swallowed, it is crucial to seek medical help or contact a Poison Control Center immediately. This information is vital for ensuring patient safety and prompt intervention in case of accidental ingestion.

Storage and Handling

The product is supplied in a container that must be stored at room temperature. It is essential to protect the product from light exposure to maintain its integrity. The bottle should be kept tightly closed when not in use to prevent contamination and degradation. Additionally, the product should be discarded after opening to ensure safety and efficacy.

Additional Clinical Information

The product is intended for topical administration. Patients should apply a thin layer to the skin tag using the provided applicator, ensuring the area dries fully. The application should be repeated twice daily for up to four weeks or as directed by a healthcare professional.

Clinicians should counsel patients that the product is for external use only and should not be applied to irritated, infected, or reddened skin. It is contraindicated for use on genital warts or warts on the face, and should not be used by individuals with diabetes or poor blood circulation. Care should be taken to avoid contact with the eyes and mucous membranes. Mild irritation may occur; however, if excessive irritation develops or if the condition worsens, patients should discontinue use and seek medical advice or contact a Poison Control Center immediately.

Drug Information (PDF)

This file contains official product information for Goodnites Skin Tag and Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)